CluenexAlnylam Pharmaceuticals ALNY
Alnylam Pharmaceuticals scores good on business quality (7.3 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Alnylam Pharmaceuticals does
Alnylam Pharmaceuticals discovers and commercializes RNA interference therapeutics, selling specialized genetic medicines directly to patients and healthcare systems. Revenue is scaling rapidly as its flagship RNAi treatments capture market share in rare genetic and cardiometabolic diseases.
- What it does best
Alnylam dominates RNA interference science, delivering a gross margin of 79.6% that outpaces NTRA at 65.2%. This technological edge is protected by deep patent estates in oligonucleotide delivery, creating high barriers to entry for competitors.
- The main risk
A heavy debt-to-equity load of 3.4x and thin interest coverage of 2.9x leave the company vulnerable to credit tightening or clinical trial delays, risking severe balance-sheet strain if cash generation falters.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin stands at 19.9% with an FCF margin of 16.5%, driving a massive ROE of 93.6%. Profitability expands reliably as revenue scales past fixed research and development costs.
Proprietary RNA interference patents lock in developers and clinical partners, placing the firm in the top decile of its sector for revenue growth and securing its high moat score.
Revenue surged 65.2% to $4.8B, landing in the top decile of its sector at the 98th percentile for growth. This top-line expansion is accelerating rapidly compared to historical annual summaries.
Total debt sits at $2.7B against $2.9B in cash, yielding a net debt position of -$210.0M. Free cash flow turned positive at $794.0M, but low interest coverage shows the balance sheet remains soft overall.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $399K outside pre-planned sales.
Our sealed record on ALNY
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Alnylam Pharmaceuticals scores good on the Cluenex quality check (7.3 of 10), measured against its own industry. Profitability is fair, moat strong, growth fast and financial health weak.
In the last 90 days of SEC Form 4 filings: 1 sold $399K outside pre-planned sales.
Oct 29, 2026.
See ALNY today
- Today's verdict on ALNY, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Alnylam Pharmaceuticals (ALNY)”, https://cluenex.com/stocks/alny/, data as of Oct 10, 2026.